Cartesian Therapeutics announces additional Descartes-08 retreatment data for myasthenia gravis

The company said Descartes-08 showed a mean MG-ADL reduction of 6.6 points at month 12 post-retreatment, with median retreatment interval of 16.6 months. It reported no new safety signals and said Phase 3 Aurora topline is expected in 1Q27, with an NDA filing expected mid-2027.